

## 4DMedical wins \$1.1 million CTCM funding to develop perfusion capability for the XV Scanner

24 July 2023

### Highlights

- Federal Minister for Health and Aged Care, the Hon. Mark Butler, MP announces award of \$1.1 million in non-dilutive funding to 4DMedical through the Clinical Translation and Commercialisation Medtech (CTCM) Program
- Funding enables expansion of XV Scanner capability beyond ventilation into perfusion
- Evolution of the world's only dedicated respiratory imaging platform positions 4DMedical as a leader in non-invasive lung diagnostics

**Melbourne, Australia, 24 July 2023:** Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the award of \$1.1 million in non-dilutive funding from the Clinical Translation and Commercialisation Medtech (CTCM) program, an initiative of the Medical Research Future Fund (MRFF), delivered by MTPConnect and supported by the Medical Device Partnering Program (MDPP) and the Medical Technology Association of Australia (MTAA).

### Broadening the capability of 4DMedical's XV Scanner


Last year, 4DMedical unveiled the world's first and only dedicated lung scanner, the XV Scanner, at the Prince of Wales Hospital in Sydney. The XV Scanner integrates 4DMedical's XV Technology® into a purpose-built platform providing doctors and patients with unprecedented and highly visual insight into lung function (ventilation, V).

4DMedical's successful application for CTCM funding will allow the Company to broaden the capability of its XV Scanner beyond ventilation to include the measurement of blood flow (perfusion, Q). This additional capability will strengthen 4DMedical's position as a leader in non-invasive lung diagnostics by providing detailed quantitative data on respiratory function via a single scan that has many advantages over existing modalities:

- rapid scan times;
- improved patient experience;
- accessible to all patient cohorts, including children, the elderly and the very unwell;
- zero contrast agents;
- low radiation; and
- unparalleled functional information, spanning both ventilation and perfusion.

### 4DMedical's product pipeline

The CTCM funding will help to accelerate the final stage of 4DMedical's long-standing product pipeline. Once complete, doctors and patients will be able to order detailed ventilation and perfusion maps of pulmonary function where the underlying images are acquired using X-ray, CT or 4DMedical's purpose-built XV Scanner. Each of these modalities offer advantages and disadvantages over each other, but importantly, together, they dramatically broaden patient access to XV Technology®.



**4DMedical MD/CEO and Founder Dr Andreas Fouras said:**

*We are extremely excited to have been awarded the \$1.1 million CTCM funding announced today. Combining both functional components of airflow and blood flow into a single analytical process represents a dramatic advancement in respiratory healthcare, providing the ideal test for phenotyping, early detection and evaluation of specific treatment responses for high-impact lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, pulmonary hypertension and pulmonary embolism.*

–ENDS–

Authorised by the 4DMedical Board of Directors.

**Contacts**

**Corporate**

CFO  
Simon Glover  
[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

**Administration**

Company Secretary  
Naomi Lawrie  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

**Media Enquiries**

TCN  
Julia Maguire  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**About 4DMedical**

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs, and identify respiratory deficiencies earlier and with greater sensitivity as patients breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com).

For personal use only



### About the Clinical Translation and Commercialisation Medtech (CTCM) Program

The CTCM program, a \$19.75 million Medical Research Future Fund initiative delivered by MTPConnect, identifies and nurtures high quality medical device projects that have commercial potential and supports their translation through early clinical trials.

To learn more, please visit <https://www.mtpconnect.org.au/programs/ctcm>

For personal use only